Compare AbbVie Inc (ABBV) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

VYMI, Vanguard's International High Dividend Yield ETF, trades at $100.285, up 1.02% today, with a bullish technical outlook from moving averages. The fund offers a diversified portfolio of international dividend stocks with a low 0.07% expense ratio and an estimated yield near 4%, attracting over $2 billion in inflows in 2026 according to The Motley Fool (2026-05-30). Recent news highlights its role in inflation protection and diversification away from U.S. tech concentration.

The outlook for VYMI is positive, driven by strong dividend growth, attractive valuations compared to U.S. markets, and investor demand for international income. Risks include currency fluctuations, economic stagnation in key regions, and competition from other dividend ETFs. Analyst sentiment is generally favorable, emphasizing its defensive qualities in uncertain macroeconomic environments.